For the year ending 2025-12-31, TYRA had -$14,579K decrease in cash & cash equivalents over the period. -$95,283K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -119,947 |
| Depreciation | 546 |
| Stock-based compensation | 28,006 |
| Accretion on marketable securities, net | -2,119 |
| Prepaid expenses and other assets | 5,080 |
| Accounts payable, accrued expenses and other liabilities | 3,369 |
| Right-of-use assets and lease liabilities, net | 83 |
| Net cash used in operating activities | -95,142 |
| Purchases of marketable securities | 101,254 |
| Maturities of marketable securities | 173,858 |
| Purchases of property and equipment | 141 |
| Net cash provided by (used in) investing activities | 72,463 |
| Proceeds from issuances of common stock under benefit plans | 8,100 |
| Proceeds from issuance of common stock and pre-funded warrants from private placement | 0 |
| Payments of issuance costs for common stock and pre-funded warrants from private placement | 0 |
| Net cash provided by financing activities | 8,100 |
| Net cash increase (decrease) for the period | -14,579 |
| Cash, cash equivalents and restricted cash at beginning of the period | 92,966 |
| Cash, cash equivalents and restricted cash at end of the period | 78,387 |
Tyra Biosciences, Inc. (TYRA)
Tyra Biosciences, Inc. (TYRA)